Advertisement
INSM or LLY or REGN
Which Stock Would AI Choose? Insmed (INSM) vs. Eli Lilly (LLY) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- INSM boasts strong long-term gains with 87% one-year return but trails YTD at -19%, driven by robust pipeline progress in rare lung diseases amid recent share weakness.
- LLY leads in market cap at over $886B, with YTD gains of 8% and obesity drug momentum, though recent monthly dips reflect legal and competitive pressures.
- REGN offers stability with flat YTD performance and 9% annual return, bolstered by Dupixent approvals and undervaluation signals from analysts.
- All three operate in biotech/pharma, but INSM focuses on rare diseases, LLY on blockbuster cardiometabolics, and REGN on immunology/oncology.
- Recent catalysts include INSM's BRINSUPRI sales beat, LLY's 42% EPS growth, and REGN's Dupixent expansions.
- Analyst targets suggest upside: INSM ~$213 (52% potential), LLY ~$1,214 (23%), REGN ~$873 (15%).
Introduction
This comparison examines INSM, LLY, and REGN, three prominent biotech and pharmaceutical stocks navigating distinct challenges in the healthcare sector. Investors seeking exposure to innovative therapies—from rare disease treatments to obesity blockbusters and immunology advancements—may find value in analyzing their relative performance, pipelines, and market positioning. Amid evolving regulatory landscapes and sector rotations, this head-to-head review highlights key metrics for traders focused on growth potential, stability, and momentum in the current market environment.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) specializes in therapies for serious rare diseases, particularly pulmonary infections, with its flagship ARIKAYCE approved for refractory nontuberculous mycobacterial lung disease. The company advances brensocatib in phase 3 for bronchiectasis and other respiratory conditions. Recent market activity has seen shares pull back, with a 2.4% daily drop and 6% monthly decline amid broader biotech volatility, trading around $140 after peaking near $213 in recent weeks. Sentiment reflects optimism from BRINSUPRI sales exceeding expectations—targeting over $1B in 2026—and analyst upgrades, including BofA's $211 target, despite pipeline setbacks like brensocatib in rhinosinusitis. Long-term, INSM delivered 87% one-year returns, underscoring growth from commercial ramps and trial progress.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) is a global leader in pharmaceuticals, excelling in cardiometabolics with Mounjaro and Zepbound driving obesity and diabetes demand. Its diversified portfolio spans oncology, immunology, and neuroscience. Shares hover near $990, up 8% YTD but down 4-10% in recent weeks amid competition and litigation concerns. Strong Q4 earnings showcased 42% EPS growth to $7.54 and $19B revenue, beating estimates, fueled by GLP-1 drugs. Analyst enthusiasm persists with $1,214 average targets, supported by pipeline expansions like orforglipron. LLY's massive scale provides resilience, though pricing pressures temper near-term momentum.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals, Inc. (REGN) develops biologics for eye diseases, inflammation, cancer, and more, with EYLEA and Dupixent as cornerstones. Recent trading around $760 shows modest YTD flatness and 9% annual gains, with minor weekly dips offset by analyst initiations like Barclays' Overweight at $923. Q4 revenue rose 3% to $3.88B, aided by Dupixent expansions and EYLEA HD uptake, though margins dipped slightly. EU approvals for Dupixent and phase 3 readouts bolster sentiment, positioning REGN as undervalued amid immunology growth. Stable execution influences positive relative performance.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of over 25 high-performing AI trading bots from its library of hundreds that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—technical, fundamental, swing, scalping—with timeframes from 5 minutes to 60 minutes, targeting sectors like aerospace, semiconductors, infrastructure, and biotech. Standouts show annualized returns up to +218%, win rates of 70-95%, and profit factors exceeding 4.0, often with low drawdowns under $2,000 on $10K portfolios. Curated for current conditions like volatility and rotations, they outperform benchmarks; for instance, biotech-leveraged bots hit +24% with 95% wins. Explore these adaptable tools tailored to market dynamics at Trending AI Robots.
Head-to-Head Comparison
INSM, LLY, and REGN contrast sharply: INSM's rare disease focus yields high-growth potential but volatility (beta implied high), versus LLY's diversified mega-cap stability and REGN's mid-cap balance. Growth drivers diverge—INSM via launches like BRINSUPRI, LLY GLP-1 dominance ($20B+ potential), REGN Dupixent/EYLEA royalties. Recent momentum favors LLY on earnings beats, but INSM leads annually while REGN lags monthly. Risks include INSM's trial failures, LLY's litigation/competition, REGN's margin squeezes. Valuations show INSM premium on revenue multiples due to catalysts, LLY elevated P/E on scale, REGN attractive at ~17x forward. Sentiment tilts bullish across, with biotech exposure unifying them amid sector recovery.
Tickeron AI Verdict
Tickeron’s AI currently leans toward INSM for its trend consistency in long-term outperformance, robust pipeline catalysts like BRINSUPRI ramp and phase 3 readouts, and highest relative upside to targets (~50%). While LLY offers unmatched stability and REGN undervaluation, INSM's positioning in underserved rare diseases signals stronger probabilistic momentum in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and REGN’s FA Score reflects 2 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- LLY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 3 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- INSM’s TA Score: 3 bullish, 6 bearish.
- LLY’s TA Score: 5 bullish, 3 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
INSM (@Biotechnology) experienced а -5.51% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.32% , and REGN (@Biotechnology) price fluctuated +0.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.75%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was +7.68%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
LLY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INSM | LLY | REGN | |
| Capitalization | 30.8B | 822B | 79.2B |
| EBITDA | -1.18B | 31.7B | 5.82B |
| Gain YTD | -17.944 | -13.595 | -2.793 |
| P/E Ratio | N/A | 40.08 | 18.07 |
| Revenue | 606M | 65.2B | 14.3B |
| Total Cash | 1.43B | 7.27B | 8.61B |
| Total Debt | 587M | 42.5B | 2.71B |
INSM | LLY | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 62 Fair valued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 37 | 20 | 75 | |
SMR RATING 1..100 | 100 | 13 | 54 | |
PRICE GROWTH RATING 1..100 | 49 | 55 | 26 | |
P/E GROWTH RATING 1..100 | 100 | 94 | 40 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for LLY (62) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (76) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than LLY’s and significantly faster than INSM’s over the last 12 months.
LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is in the same range as INSM (37) in the Biotechnology industry, and is somewhat better than the same rating for REGN (75) in the Biotechnology industry. This means that LLY's stock grew similarly to INSM’s and somewhat faster than REGN’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (54) in the Biotechnology industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that LLY's stock grew somewhat faster than REGN’s and significantly faster than INSM’s over the last 12 months.
REGN's Price Growth Rating (26) in the Biotechnology industry is in the same range as INSM (49) in the Biotechnology industry, and is in the same range as LLY (55) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to INSM’s and similarly to LLY’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for LLY (94) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INSM (100) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than LLY’s and somewhat faster than INSM’s over the last 12 months.
| INSM | LLY | REGN | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 74% | N/A |
| Stochastic ODDS (%) | 4 days ago 78% | 4 days ago 70% | 4 days ago 75% |
| Momentum ODDS (%) | 4 days ago 74% | 4 days ago 61% | 4 days ago 52% |
| MACD ODDS (%) | 4 days ago 66% | 4 days ago 67% | 4 days ago 49% |
| TrendWeek ODDS (%) | 4 days ago 72% | 4 days ago 59% | 4 days ago 66% |
| TrendMonth ODDS (%) | 4 days ago 74% | 4 days ago 57% | 4 days ago 60% |
| Advances ODDS (%) | 20 days ago 71% | 12 days ago 71% | 20 days ago 64% |
| Declines ODDS (%) | 5 days ago 73% | 5 days ago 55% | 5 days ago 51% |
| BollingerBands ODDS (%) | 4 days ago 70% | 4 days ago 81% | 4 days ago 49% |
| Aroon ODDS (%) | 4 days ago 84% | 4 days ago 57% | 4 days ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MAPP | 27.35 | 0.20 | +0.75% |
| Harbor Multi-Asset Explorer ETF | |||
| MOAT | 102.49 | 0.19 | +0.19% |
| VanEck Morningstar Wide Moat ETF | |||
| VUSE | 68.19 | -0.01 | -0.01% |
| Vident U.S. Equity Strategy ETF | |||
| FIAX | 17.71 | -0.01 | -0.04% |
| Nicholas Fixed Income Alternative ETF | |||
| MAGY | 45.56 | -0.32 | -0.70% |
| Roundhill Magnificent Seven Covered Call ETF | |||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.